Asymmetric Carbon–Carbon Bond Formation γ to a Carbonyl Group: Phosphine-Catalyzed Addition of Nitromethane to Allenes

Sean W. Smith and Gregory C. Fu*

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

SUPPORTING INFORMATION

Table of Contents

I.	Preparation of Allenes	S-1
II.	Phosphine-Catalyzed Asymmetric γ Additions	S-7
III.	Determination of Absolute Stereochemistry	S–15
IV.	Data (¹ H NMR spectra and HPLC traces for reactions with (S)-1)	S–16

I. Preparation of Allenes

The yields have not been optimized.

Synthesis of Allenes (representative procedure): A 300-mL flask was charged with a phosphorane (14.5 g, 40.0 mmol), evacuated, and back-filled with argon. CH_2Cl_2 (200 mL) and Et_3N (6.1 mL, 40 mmol) were added via syringe, and the solution was cooled to -78 °C. The acid chloride (40.0 mmol) was then added dropwise via syringe over five min. The solution was allowed to warm to room temperature over 3-4 hours, and then the reaction was quenched by the addition of silica gel. After removal of the solvent on a rotary evaporator, the product (adsorbed on silica) was loaded onto a pre-packed column of silica gel and purified via flash chromatography (hexanes/ethyl acetate), which furnished the allene as an oil.



(±)-*N*-**Methoxy**-*N*-**methylhepta-2,3-dienamide.** Prepared from *N*-methoxy-*N*-methyl-2-(triphenylphosphoranylidene)acetamide and pentanoyl chloride via the

representative procedure (purification by flash chromatography: 25% EtOAc in hexanes; 40% yield).

¹H NMR (CDCl₃, 500 MHz) δ 6.15 (quintet, *J* = 2.9 Hz, 1H), 5.64 (q, *J* = 6.8 Hz, 1H), 3.71 (s, 3H), 3.23 (s, 3H), 2.14-2.09 (m, 2H), 1.49 (sextet, *J* = 7.4 Hz, 2H), 0.95 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 212.2, 166.1, 95.2, 86.3, 61.5, 32.6, 29.7, 22.2, 13.6.

IR (film) 3567, 3291, 3042, 2961, 2935, 2873, 2361, 2339, 1958, 1653, 1463, 1424, 1364 cm⁻¹.

LRMS (ES+) calcd for $C_9H_{16}NO_2$ (M+H⁺) 170, found 170.



(±)-*N*-Methoxy-*N*-methylpenta-2,3-dienamide. Prepared from *N*-methoxy-*N*-methyl-2-(triphenylphosphoranylidene)acetamide and propionyl chloride via the representative procedure (purification by flash chromatography: 25% EtOAc in hexanes; 33% yield).

¹H NMR (CDCl₃, 500 MHz) δ 6.20-6.10 (m, 1H), 5.61 (quintet, *J* = 7.3 Hz, 1H), 3.71 (s, 3H), 3.23 (s, 3H), 1.80-1.76 (m, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 212.9, 166.1, 90.3, 85.9, 61.8, 32.7, 13.1. IR (film) 3567, 2974, 2936, 2361, 2339, 1960, 1653, 1457, 1421, 1358 cm⁻¹. LRMS (ES+) calcd for $C_7H_{12}NO_2$ (M+H⁺) 142, found 142.



(±)-5-Cyclopentyl-*N*-methoxy-*N*-methylpenta-2,3-dienamide. Prepared from *N*-methoxy-*N*-methyl-2-(triphenylphosphoranylidene)acetamide and 3-cyclopentyl-propanoyl chloride via the representative procedure (purification by flash chromatography: 25% EtOAc in hexanes; 41% yield).

¹H NMR (CDCl₃, 500 MHz) δ 6.16-6.12 (m, 1H), 5.63 (q, *J* = 7.3 Hz, 1H), 3.71 (s, 3H), 3.26 (s, 3H), 2.14 (dt, *J* = 7.2, 2.8 Hz, 2H), 1.95 (septet, *J* = 7.6 Hz, 1H), 1.83-1.75 (m, 2H), 1.64-1.47 (m, 4H), 1.22-1.14 (2H).

¹³C NMR (CDCl₃, 125 MHz) δ 212.6, 166.2, 94.8, 85.9, 61.8, 39.7, 34.2, 32.7, 32.4, 25.4. IR (film) 3290, 2948, 2867, 2361, 2339, 1654, 1424, 1363 cm⁻¹.

LRMS (ES+) calcd for $C_{12}H_{20}NO_2$ (M+H⁺) 210, found 210.



(±)-*N*-Methoxy-*N*,5-dimethylhexa-2,3-dienamide. Prepared from *N*-methoxy-*N*-methyl-2-(triphenylphosphoranylidene)acetamide and isovaleroyl chloride via the representative procedure (purification by flash chromatography: 25% EtOAc in hexanes; 44% yield).

¹H NMR (CDCl₃, 500 MHz) δ 6.20 (q, *J* = 3.1 Hz, 1H), 5.66 (t, *J* = 6.1 Hz, 1H), 3.71 (s, 3H), 3.23 (s, 3H), 2.52-2.42 (m, 1H), 1.08 (d, *J* = 6.7 Hz, 6H).

¹³C NMR (CDCl₃, 125 MHz) δ 211.1, 166.1, 102.6, 87.4, 61.8, 32.6, 27.7, 22.5, 22.3. IR (film) 3291, 2963, 2937, 2871, 2361, 2339, 1957, 1653, 1465, 1384 cm⁻¹. LRMS (ES+) calcd for $C_9H_{16}NO_2$ (M+H⁺) 170, found 170.



(±)-8-(*tert*-Butyldimethylsilyloxy)-*N*-methoxy-*N*-methylocta-2,3-dienamide. Prepared from *N*-methoxy-*N*-methyl-2-(triphenylphosphoranylidene)acetamide and 6-(*tert*-butyldimethylsilyloxy)hexanoyl chloride via the representative procedure (purification by flash chromatography: 25% EtOAc in hexanes; 10% yield).

¹H NMR (CDCl₃, 300 MHz) δ 6.09-6.06 (m, 1H), 5.57 (t, *J* = 6.7 Hz, 1H), 3.63 (s, 3H), 3.56-3.52 (m, 2H), 3.16 (s, 3H), 2.15-2.05 (m, 2H), 1.60-1.38 (m, 4H), 0.81 (s, 9H), -0.04 (s, 6H).

¹³C NMR (CDCl₃, 125 MHz) δ 212.2, 166.1, 95.5, 86.5, 63.0, 61.8, 32.7, 32.3, 27.4, 26.1, 25.3, 18.5, –5.1.

IR (film) 3308, 2935, 2857, 2361, 2340, 1959, 1658, 1472 cm⁻¹. LRMS (ES+) calcd for $C_{16}H_{32}NO_3Si$ (M+H⁺) 314, found 314.



(±)-Methyl 8-(methoxy(methyl)amino)-8-oxoocta-5,6-dienoate. Prepared from *N*-methoxy-*N*-methyl-2-(triphenylphosphoranylidene)acetamide and methyl adipoyl chloride via the representative procedure (purification by flash chromatography: 25% EtOAc in hexanes; 25% yield).

¹H NMR (CDCl₃, 500 MHz) δ 6.18 (quintet, *J* = 2.9 Hz, 1H), 5.63 (q, *J* = 6.7 Hz, 1H), 3.71 (s, 3H), 3.66 (s, 3H), 3.23 (s, 3H), 2.39 (t, *J* = 7.4 Hz, 2H), 2.18 (qd, *J* = 7.1, 3.0 Hz, 2H), 1.80 (quintet, *J* = 7.4 Hz, 2H).

¹³C NMR (CDCl₃, 125 MHz) δ 212.3, 173.9, 165.9, 94.7, 86.9, 61.9, 51.7, 33.3, 32.8, 27.1, 24.1.

IR (film) 3282, 2951, 2361, 2339, 1959, 1734, 1653, 1639, 1457 cm⁻¹. LRMS (ES+) calcd for $C_{11}H_{18}NO_4$ (M+H⁺) 228, found 228.



(±)-Methyl 10-(methoxy(methyl)amino)-10-oxodeca-7,8-dienoate. Prepared from *N*-methoxy-*N*-methyl-2-(triphenylphosphoranylidene)acetamide and methyl 8-chloro-8-oxooctanoate chloride¹ via the representative procedure (purification by flash chromatography: 25% EtOAc in hexanes; 21% yield).

¹H NMR (CDCl₃, 500 MHz) δ 6.18-6.14 (m, 1H), 5.52 (q, *J* = 2.3 Hz, 1H), 3.61 (s, 3H), 3.55 (s, 3H), 3.13 (s, 3H), 2.20 (t, *J* = 7.4 Hz, 2H), 2.06-2.01 (m, 2H), 1.56-1.49 (m, 2H), 1.42-1.35 (m, 2H), 1.31-1.24 (m, 2H).

¹³C NMR (CDCl₃, 125 MHz) δ 212.2, 174.2, 166.0, 95.3, 86.5, 61.8, 51.5, 34.0, 32.7, 28.6, 28.5, 27.4, 24.8.

IR (film) 3288, 2937, 2859, 2361, 2338, 1958, 1734, 1653 cm⁻¹. LRMS (ES+) calcd for $C_{13}H_{22}NO_4$ (M+H⁺) 256, found 256.



(±)-*N*-Methoxy-*N*-methyltrideca-2,3,12-trienamide. Prepared from *N*-methoxy-*N*-methyl-2-(triphenylphosphoranylidene)acetamide and 10-undecenoyl chloride via the representative procedure (purification by flash chromatography: 25% EtOAc in hexanes; 39% yield).

¹H NMR (CDCl₃, 500 MHz) δ 6.15 (quintet, *J* = 2.9 Hz, 1H), 5.80 (qt, *J* = 10.3, 6.7 Hz, 1H), 5.64 (q, *J* = 6.9 Hz, 1H), 4.98 (dq, *J* = 17.1, 1.6 Hz, 1H), 4.92 (dquintet, *J* = 10.2, 1.2 Hz, 1H), 3.71 (s, 3H), 3.24 (s, 3H), 2.13 (qd, *J* = 7.0, 3.0 Hz, 2H), 2.05-2.00 (m, 2H), 1.46 (quintet, *J* = 6.4 Hz, 2H), 1.40-1.27 (m, 8H).

¹³C NMR (CDCl₃, 125 MHz) δ 212.3, 166.1, 139.4, 114.3, 95.7, 86.5, 61.9, 34.0, 29.4, 29.3, 29.23, 29.21, 29.12, 29.10, 27.8.

IR (film) 3075, 2927, 2855, 2361, 2338, 1959, 1653, 1464, 1423, 1362 cm⁻¹. LRMS (ES+) calcd for $C_{15}H_{26}NO_2$ (M+H⁺) 252, found 252.

⁽¹⁾ Schinzer, D.; Limberg, A.; Böhm, O. M. Chem. Eur. J. 1996, 2, 1477–1482.



(±)-(*Z*)-*N*-Methoxy-*N*-methylnonadeca-2,3,10-trienamide. Prepared from *N*-methoxy-*N*-methyl-2-(triphenylphosphoranylidene)acetamide and oleoyl chloride via the representative procedure (purification by flash chromatography: 25% EtOAc in hexanes; 55% yield).

¹H NMR (CDCl₃, 500 MHz) δ 6.15 (quintet, *J* = 2.9 Hz, 1H), 5.64 (q, *J* = 6.9 Hz, 1H), 5.37-5.30 (m, 2H), 3.71 (s, 3H), 3.24 (s, 3H), 2.16-2.11 (m, 2H), 2.02-1.99 (m, 4H), 1.50 (m, 2H), 1.37-1.22 (m, 18H), 0.88 (t, *J* = 6.9 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 212.3, 166.2, 130.1, 129.9, 95.6, 86.4, 61.8, 32.7, 32.1, 29.9, 29.8, 29.7, 29.53, 29.52, 29.2, 29.1, 29.0, 27.8, 27.4, 27.3, 22.9, 14.3.

IR (film) 3300, 3003, 2923, 2853, 2361, 2338, 1959, 1653, 1457, 1420, 1362 cm⁻¹. LRMS (ES+) calcd for $C_{22}H_{40}NO_2$ (M+H⁺) 350, found 350.



(±)-Methyl hepta-2,3-dienoate [111425-91-5]. Prepared from methyl (triphenyl-phosphoranylidene)acetate and pentanoyl chloride via the representative procedure (purification by distillation; 71% yield).

¹H NMR (CDCl₃, 500 MHz) δ 5.59-5.52 (m, 2H), 3.68 (s, 3H), 2.10-2.05 (m, 2H), 1.48-1.41 (m, 2H), 0.91 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 212.6, 166.9, 95.4, 88.0, 52.1, 29.7, 22.1, 13.6.

IR (film) 2960, 2935, 2875, 2361, 2337, 1961, 1723, 1437, 1262 cm⁻¹.

LRMS (ES+) calcd for $C_8H_{13}O_2$ (M+H⁺) 141, found 141.



(±)-*tert*-**Butyl hepta-2,3-dienoate [151860-31-0].** Prepared from (*tert*-butoxycarbonyl-methylene)triphenylphosphorane and pentanoyl chloride via the representative procedure (purification by flash chromatography: 5% EtOAc in hexanes; 38% yield).

¹H NMR (CDCl₃, 500 MHz) δ 5.55 (q, *J* = 6.9 Hz, 1H), 5.47 (q, *J* = 2.6 Hz, 1H), 2.09-2.02 (m, 2H), 1.52-1.42 (m, 11H), 0.95 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 212.1, 165.8, 95.0, 89.9, 80.8, 29.8, 28.3, 22.2, 13.7.

IR (film) 3004, 2967, 2934, 2875, 2361, 2338, 1960, 1717, 1368, 1147 cm⁻¹. LRMS (ES+) calcd for $C_{11}H_{19}O_2$ (M+H⁺) 183, found 183.

(EtO)₂(O)P_____n-Pent

(±)-Diethyl octa-1,2-dienylphosphonate [344554-28-5]. Prepared according to a literature procedure (purification by flash chromatography: $20 \rightarrow 100\%$ EtOAc in hexanes; 75% yield).²

¹H NMR (CDCl₃, 500 MHz) δ 5.43 (sextet, *J* = 7.0 Hz, 1H), 5.29 (sextet, *J* = 3.4 Hz, 1H), 4.14-4.07 (m, 4H), 2.09 (quintet of doublets, *J* = 7.2, 3.4 Hz, 2H), 1.46-1.41 (m, 2H), 1.35-1.29 (m, 10H), 1.33 (t, *J* = 7.0 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 211.9, 92.4, 80.8, 79.2, 62.2, 31.2, 28.67, 28.64, 27.4, 22.5, 16.4, 14.1.

IR (film) 3482, 2980, 2958, 2931, 2872, 2859, 2360, 2338, 1955, 1258 cm⁻¹. LRMS (ES+) calcd for $C_{12}H_{24}O_3P$ (M+H⁺) 247, found 247.

⁽²⁾ Altenbach, H.-J.; Korff, R. Tetrahedron Lett. 1981, 22, 5175–5178.

II. Phosphine-Catalyzed Asymmetric γ Additions

General Procedure. In a glovebox, catalyst (*S*)-**1** (29 mg, 0.075 mmol; 0.10 equiv) and phenol (7.0 mg, 0.075 mmol; 0.10 equiv) were added to an oven-dried 20-mL vial. These solids were dissolved in anhydrous dioxane (15 mL), and then nitromethane (225 μ L, 4.15 mmol; 5.5 equiv) and the allene (0.75 mmol; 1.0 equiv) were added via syringe. The vial was capped and removed from the glovebox, and the reaction mixture was stirred at room temperature for 15 h. The solvent was then evaporated, and the product was purified by flash chromatography.

Glovebox-free Procedure (Table 2, entry 2). On a benchtop, catalyst (*S*)-1 (43.5 mg, 0.113 mmol; 0.15 equiv; with 10% (*S*)-1, a small amount of unreacted allene was observed after 15 h) and phenol (10.5 mg, 0.113 mmol; 0.15 equiv) were added to an oven-dried 20-mL vial. The vial was capped with a septum, and then it was evacuated and refilled with argon (three cycles). Next, anhydrous dioxane (15 mL), nitromethane (225 μ L, 4.15 mmol; 5.5 equiv), and (±)-*N*-methoxy-*N*-methylhepta-2,3-dienamide (127 mg, 0.75 mmol; 1.0 equiv) were added in order via syringe through the septum. The reaction mixture was stirred at room temperature for 15 h. It was then concentrated and purified by flash chromatography (25% EtOAc in pentane), which afforded the desired product as a colorless oil (140 mg, 81% yield) with 93% ee.



(*E*)-*N*-Methoxy-*N*-4-dimethyl-5-nitropent-2-enamide (Table 2, entry 1). The compound was prepared according to the general procedure with (±)-*N*-methoxy-*N*-methylpenta-2,3-dienamide (106 mg, 0.75 mmol). After purification by flash chromatography (30% EtOAc in hexanes), the title compound was isolated as a colorless oil (144 mg, 95% yield) with 97% ee.

 $[\alpha]_{D}^{22} = -45$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK OD-H column; 5.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 38.7 min (minor), 44.5 min (major).

The second run was performed with (R)-1. The product was isolated as a colorless oil (140 mg, 93% yield) with 97% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.73 (dd, *J* = 15.4, 7.8 Hz, 1H), 6.45 (d, *J* = 15.4 Hz, 1H), 4.37 (dd, *J* = 12.2, 7.7 Hz, 1H), 4.31 (dd, *J* = 12.2, 7.0 Hz, 1H), 3.63 (s, 3H), 3.18 (s, 3H), 3.24-3.15 (m, 1H), 1.15 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 165.9, 145.2, 120.6, 79.9, 62.0, 35.8, 32.4, 17.0.

IR (film) 3287, 2972, 2361, 2339, 1669, 1558 cm⁻¹.

LRMS (ES+) calcd for $C_8H_{15}N_2O_4$ (M+H⁺) 203, found 203.



(*E*)-*N*-Methoxy-*N*-methyl-4-(nitromethyl)hept-2-enamide (Table 2, entry 2). The compound was prepared according to the general procedure with (±)-*N*-methoxy-*N*-methylhepta-2,3-dienamide (127 mg, 0.75 mmol). After purification by flash chromatography (30% EtOAc in hexanes), the title compound was isolated as a colorless oil (137 mg, 80% yield) with 93% ee.

 $[\alpha]_{D}^{22} = -30$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK OD-H column; 5.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 24.5 min (major), 28.7 min (minor).

The second run was performed with (R)-1. The product was isolated as a colorless oil (141 mg, 82% yield) with 93% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.63 (dd, J = 15.4, 9.1 Hz, 1H), 6.44 (d, J = 15.4 Hz, 1H), 4.38 (dd, J = 12.3, 5.9 Hz, 1H), 4.30 (dd, J = 12.2, 8.9 Hz, 1H), 3.61 (s, 3H), 3.17 (s, 3H), 3.09-3.01 (m, 1H), 1.46-1.17 (m, 4H), 0.85 (t, J = 7.2 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 165.7, 144.2, 122.0, 79.1, 62.0, 41.3, 33.6, 32.4, 20.0, 13.9. IR (film) 2961, 2935, 2874, 2361, 2338, 1668, 1635, 1558, 1379 cm⁻¹. LRMS (ES+) calcd for $C_{10}H_{19}N_2O_4$ (M+H⁺) 231, found 231.



(*E*)-5-Cyclopentyl-*N*-methoxy-*N*-methyl-4-(nitromethyl)pent-2-enamide (Table 2, entry 3). The compound was prepared according to the general procedure with (±)-5-cyclopentyl-*N*-methoxy-*N*-methylpenta-2,3-dienamide (157 mg, 0.75 mmol). After purification by flash chromatography (30% EtOAc in hexanes), the title compound was isolated as a colorless oil (146 mg, 72% yield) with 87% ee.

 $[\alpha]_D^{22} = -3.5$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK OD-H column; 3.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 33.7 min (major), 46.2 min (minor).

The second run was performed with (R)-1. The product was isolated as a colorless oil (152 mg, 75% yield) with 86% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.65 (dd, J = 15.4, 9.4 Hz, 1H), 6.47 (d, J = 15.4 Hz, 1H), 4.38 (dd, J = 12.3, 5.8 Hz, 1H), 4.30 (dd, J = 12.2, 9.0 Hz, 1H), 3.63 (s, 3H), 3.18 (s, 3H), 3.13-3.04 (m, 1H), 1.75-1.70 (m, 3H), 1.58-1.36 (m, 6H), 1.05-1.00 (m, 2H).

¹³C NMR (CDCl₃, 125 MHz) δ 165.8, 144.4, 122.0, 79.4, 62.0, 41.0, 38.0, 37.4, 33.3, 32.1, 25.2.

IR (film) 2941, 2867, 2361, 2339, 1669, 1653, 1635, 1558 cm⁻¹. LRMS (ES+) calcd for $C_{13}H_{23}N_2O_4$ (M+H⁺) 271, found 271.



(*E*)-*N*-Methoxy-*N*,5-dimethyl-4-(nitromethyl)hex-2-enamide (Table 2, entry 4). The compound was prepared according to the general procedure (except 15% catalyst was used) with (±)-*N*-methoxy-*N*,5-dimethylhexa-2,3-dienamide (127 mg, 0.75 mmol). After purification by flash chromatography (30% EtOAc in hexanes), the title compound was isolated as a colorless oil (102 mg, 60% yield) with 81% ee.

 $[\alpha]_{D}^{22} = -30$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK OD-H column; 5.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 19.7 min (major), 24.0 min (minor).

The second run was performed with (R)-1. The product was isolated as a colorless oil (108 mg, 63% yield) with 81% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.72 (dd, *J* = 15.4, 9.5 Hz, 1H), 6.44 (d, *J* = 15.4 Hz, 1H), 4.49 (dd, *J* = 12.2, 5.1 Hz, 1H), 4.35 (dd, *J* = 12.1, 9.8 Hz, 1H), 3.63 (s, 3H), 3.19 (s, 3H), 2.91 (septet, *J* = 5.4 Hz, 1H), 1.80 (sextet, *J* = 6.7 Hz, 1H), 0.92 (dd, *J* = 13.0, 6.7 Hz, 6H).

¹³C NMR (CDCl₃, 125 MHz) δ 165.6, 142.5, 122.8, 77.9, 62.0, 47.6, 32.4, 30.0, 20.5, 19.2. IR (film) 2965, 2876, 2361, 2338, 1668, 1653, 1635, 1558, 1472, 1457 cm⁻¹. LRMS (ES+) calcd for $C_{10}H_{19}N_2O_4$ (M+H⁺) 231, found 231.



(*E*)-8-(*tert*-Butyldimethylsilyloxy)-*N*-methoxy-*N*-methyl-4-(nitromethyl)oct-2enamide (Table 2, entry 5). The compound was prepared according to the general procedure with (±)-8-(*tert*-butyldimethylsilyloxy)-*N*-methoxy-*N*-methylocta-2,3dienamide (235 mg, 0.75 mmol). After purification by flash chromatography (25% EtOAc in hexanes), the title compound was isolated as a colorless oil (156 mg, 56% yield) with 92% ee.

 $[\alpha]_{D}^{22} = -19$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK OD-H column; 5.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 16.6 min (major), 18.4 min (minor).

The second run was performed with (R)-1. The product was isolated as a colorless oil (163 mg, 58% yield) with 92% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.65 (dd, *J* = 15.4, 9.1 Hz, 1H), 6.53 (d, *J* = 15.4 Hz, 1H), 4.39 (dd, *J* = 12.3, 6.0 Hz, 1H), 4.32 (dd, *J* = 12.3, 9.0 Hz, 1H), 3.63 (s, 3H), 3.57-3.50 (m, 2H), 3.18 (s, 3H), 3.09-3.02 (m, 1H), 1.54-1.24 (m, 6H), 0.83 (s, 9H), -0.01 (s, 6H).

¹³C NMR (CDCl₃, 125 MHz) δ 165.6, 144.1, 122.1, 79.0, 62.9, 62.0, 41.6, 32.6, 31.4, 26.1, 23.3, 18.5, -5.1.

IR (film) 2933, 2858, 2361, 2339, 1668, 1653, 1635, 1557, 1380 cm⁻¹.

LRMS (ES+) calcd for $C_{17}H_{35}N_2O_5Si$ (M+H⁺) 375, found 375.



(*E*)-Methyl 8-(methoxy(methyl)amino)-5-(nitromethyl)-8-oxooct-6-enoate (Table 2, entry 6). The compound was prepared according to the general procedure with (±)-methyl 8-(methoxy(methyl)amino)-8-oxoocta-5,6-dienoate (170 mg, 0.75 mmol). After purification by flash chromatography ($15 \rightarrow 50\%$ EtOAc in hexanes), the title compound was isolated as a colorless oil (165 mg, 76% yield) with 94% ee.

 $[\alpha]_{D}^{22} = -30$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK AD-H column; 5.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 59.9 min (major), 74.3 min (minor).

The second run was performed with (R)-1. The product was isolated as a colorless oil (158 mg, 73% yield) with 92% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.61 (dd, *J* = 15.4, 9.1 Hz, 1H), 6.47 (d, *J* = 15.5 Hz, 1H), 4.39 (dd, *J* = 12.4, 6.0 Hz, 1H), 4.31 (dd, *J* = 12.3, 8.8 Hz, 1H), 3.61 (s, 3H), 3.58 (s, 3H), 3.16 (s, 3H), 3.08-3.00 (m, 1H), 2.25 (t, *J* = 6.9 Hz, 2H), 1.64-1.41 (m, 4H).

¹³C NMR (CDCl₃, 125 MHz) δ 173.5, 165.6, 143.5, 122.5, 78.8, 62.0, 51.8, 41.3, 33.6, 32.4, 30.8, 22.2.

IR (film) 2952, 2871, 2361, 2338, 1734, 1664, 1635, 1557 cm⁻¹.

LRMS (ES+) calcd for $C_{12}H_{21}N_2O_6$ (M+H⁺) 289, found 289.



(*E*)-Methyl 10-(methoxy(methyl)amino)-7-(nitromethyl)-10-oxodec-8-enoate (Table 2, entry 7). The compound was prepared according to the general procedure with (±)-methyl 10-(methoxy(methyl)amino)-10-oxodeca-7,8-dienoate (191 mg, 0.75 mmol). After purification by flash chromatography ($20 \rightarrow 50\%$ EtOAc in hexanes), the title compound was isolated as a colorless oil (195 mg, 82% yield) with 92% ee.

 $[\alpha]_{D}^{22} = -26$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK OD-H column; 5.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 56.7 min (major), 63.5 min (minor).

The second run was performed with (R)-1. The product was isolated as a colorless oil (193 mg, 82% yield) with 92% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.58 (dd, J = 15.4, 9.1 Hz, 1H), 6.40 (d, J = 15.4 Hz, 1H), 4.35 (dd, J = 12.3, 5.9 Hz, 1H), 4.28 (dd, J = 12.3, 8.7 Hz, 1H), 3.58 (s, 3H), 3.55 (s, 3H), 3.13 (s, 3H), 3.02-2.94 (m, 1H), 2.19 (t, J = 7.4 Hz, 3H), 1.52-1.16 (m, 7H).

¹³C NMR (CDCl₃, 125 MHz) δ 174.0, 165.7, 144.0, 122.1, 79.0, 61.9, 51.6, 41.4, 33.9, 32.3, 31.3, 28.9, 26.5, 24.7.

IR (film) 2938, 2861, 2361, 2339, 1734, 1558 cm⁻¹.

LRMS (ES+) calcd for $C_{14}H_{25}N_2O_6$ (M+H⁺) 317, found 317.



(*E*)-*N*-Methoxy-*N*-methyl-4-(nitromethyl)trideca-2,12-dienamide (Table 2, entry 8). The compound was prepared according to the general procedure with (\pm)-*N*-methoxy-*N*-methyltrideca-2,3,12-trienamide (189 mg, 0.75 mmol). After purification by flash chromatography (5 \rightarrow 40% EtOAc in hexanes), the title compound was isolated as a colorless oil (199 mg, 85% yield) with 92% ee.

 $[\alpha]_{D}^{22} = -26$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK AD-H column; 5.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 14.7 min (major), 18.0 min (minor).

The second run was performed with (*R*)-1. The product was isolated as a colorless oil (190 mg, 81% yield) with 92% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.62 (dd, *J* = 15.4, 9.1 Hz, 1H), 6.43 (d, *J* = 15.4 Hz, 1H), 5.71 (ddt, *J* = 17.0, 10.2, 6.7 Hz, 1H), 4.93-4.83 (m, 2H), 4.37 (dd, *J* = 12.3, 6.0 Hz, 1H), 4.29 (dd, *J* = 12.1, 8.8 Hz, 1H), 3.60 (s, 3H), 3.16 (s, 3H), 3.06-2.98 (m, 1H), 1.97-1.93 (m, 2H), 1.48-1.14 (m, 12H).

¹³C NMR (CDCl₃, 125 MHz) δ 165.7, 144.3, 139.2, 122.0, 114.4, 79.1, 61.9, 60.5, 41.5, 33.9, 31.6, 29.4, 29.1, 29.0, 26.8, 14.3.

IR (film) 3289, 3075, 2925, 2855, 2361, 2339, 1653 cm⁻¹.

LRMS (ES+) calcd for $C_{16}H_{29}N_2O_4$ (M+H⁺) 313, found 313.



(2*E*,11*Z*)-*N*-Methoxy-*N*-methyl-4-(nitromethyl)icosa-2,11-dienamide (Table 2, entry 9). The compound was prepared according to the general procedure with (±)-(*Z*)-*N*-methoxy-*N*-methylnonadeca-2,3,10-trienamide (262 mg, 0.75 mmol). After purification by flash chromatography (7 \rightarrow 14% EtOAc in hexanes), the title compound was isolated as a colorless oil (257 mg, 83% yield) with 93% ee.

 $[\alpha]_{D}^{22} = -24$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK OD-H column; 1.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 57.4 min (major), 64.0 min (minor).

The second run was performed with (R)-1. The product was isolated as a colorless oil (260 mg, 84% yield) with 93% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.64 (dd, J = 15.4, 9.4 Hz, 1H), 6.47 (dd, J = 15.4 Hz, 1H), 5.31-5.20 (m, 2H), 4.38 (dd, J = 12.3, 6.0 Hz, 1H), 4.30 (dd, J = 12.1, 8.9 Hz, 1H), 3.61 (s, 3H), 3.17 (s, 3H), 3.08-2.98 (m, 1H), 2.00-1.88 (m, 4H), 1.48-1.10 (m, 22H), 0.81 (t, J = 6.5 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 165.8, 144.3, 130.2, 129.7, 122.0, 79.1, 61.9, 41.5, 36.8, 32.4, 32.0, 31.6, 29.9, 29.8, 29.7, 29.5, 29.4, 29.2, 27.4, 27.3, 26.9, 22.9, 14.3.

IR (film) 3003, 2926, 2855, 2361, 2339, 1667, 1635, 1557, 1464 cm⁻¹.

LRMS (ES+) calcd for $C_{23}H_{43}N_2O_4$ (M+H⁺) 411, found 411.



(*E*)-Methyl 4-(nitromethyl)hept-2-enoate (Table 3, entry 1). The compound was prepared according to the general procedure with (\pm)-methyl hepta-2,3-dienoate (105 mg, 0.75 mmol). After purification by flash chromatography (30% hexanes in CH₂Cl₂), the title compound was isolated as a colorless oil (109 mg, 72% yield) with 92% ee.

 $[\alpha]_{D}^{22} = -32$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK OD-H column; 1.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 24.8 min (minor), 32.7 min (major).

The second run was performed with (R)-1. The product was isolated as a colorless oil (113 mg, 74% yield) with 93% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.72 (dd, *J* = 15.6, 9.1 Hz, 1H), 5.90 (d, *J* = 15.7 Hz, 1H), 4.42 (dd, *J* = 12.3, 5.9 Hz, 1H), 3.85 (dd, *J* = 12.3, 8.7 Hz, 1H), 3.73 (s, 3H), 3.10-3.03 (m, 1H), 1.50-1.25 (m, 4H), 0.91 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 166.3, 146.1, 124.2, 78.9, 52.0, 41.0, 33.5, 20.0, 13.9. IR (film) 2960, 2935, 2875, 2361, 2339, 1717, 1661, 1558, 1436 cm⁻¹. LRMS (ES+) calcd for $C_9H_{16}NO_4$ (M+H⁺) 202, found 202.



(*E*)-*tert*-**Butyl 4-(nitromethyl)hept-2-enoate (Table 3, entry 2).** The compound was prepared according to the general procedure with (±)-*tert*-butyl hepta-2,3-dienoate (137 mg, 0.75 mmol). After purification by flash chromatography (10% EtOAc in hexanes), the title compound was isolated as a colorless oil (173 mg, 95% yield) with 90% ee.

 $[\alpha]_{D}^{22} = -29$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK OD-H column; 1.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 13.6 min (minor), 17.4 min (major).

The second run was performed with (R)-1. The product was isolated as a colorless oil (168 mg, 93% yield) with 90% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.56 (dd, *J* = 15.6, 9.0 Hz, 1H), 5.77 (d, *J* = 15.6 Hz, 1H), 4.37 (dd, *J* = 12.3, 6.1 Hz, 1H), 4.31 (dd, *J* = 12.3, 8.5 Hz, 1H), 3.04-2.96 (m, 1H), 1.42-1.20 (m, 13H), 0.86 (t, *J* = 6.6 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 165.1, 144.6, 126.1, 80.9, 78.9, 40.8, 33.5, 28.2, 20.0, 13.9. IR (film) 2964, 2934, 2875, 2361, 2339, 1713, 1654, 1554, 1368, 1159 cm⁻¹. LRMS (ES+) calcd for $C_8H_{12}NO_4$ (M-*t*-Bu⁺) 186, found 186.



(*E*)-Diethyl 3-(nitromethyl)oct-1-enylphosphonate (Table 3, entry 3). The compound was prepared according to the general procedure (except 3.0 equiv of phenol was used and the reaction mixture was heated at 60 °C) with (±)-diethyl octa-1,2-dienylphosphonate (185 mg, 0.75 mmol). After purification by flash chromatography (70% EtOAc in hexanes), the title compound was isolated as a colorless oil (203 mg, 89% yield) with 75% ee.

 $[\alpha]_{D}^{22} = -18$ (c = 1.0, CHCl₃). HPLC analysis of the product: Daicel CHIRALPAK OD-H column; 2.0% *i*-PrOH in hexanes; 1.0 mL/min; retention times: 41.4 min (minor), 46.7 min (major).

The second run was performed with (R)-1. The product was isolated as a colorless oil (193 mg, 84% yield) with 72% ee.

¹H NMR (CDCl₃, 500 MHz) δ 6.45 (ddd, *J* = 21.6, 17.1, 8.7 Hz, 1H), 5.64 (dd, *J* = 18.9, 17.1 Hz, 1H), 4.35 (dd, *J* = 12.2, 5.6 Hz, 1H), 4.26 (dd, *J* = 12.2, 9.0 Hz, 1H), 4.01-3.87 (m, 4H), 2.96-2.89 (m, 1H), 1.42-1.30 (m, 2H), 1.28-1.11 (m, 12H), 0.77 (t, *J* = 6.6 Hz, 3H).

¹³C NMR (CDCl₃, 125 MHz) δ 150.6, 121.7, 78.8, 62.0, 43.2, 43.0, 31.5, 31.1, 26.4, 22.5, 16.5, 16.4, 14.0.

IR (film) 2958, 2932, 2860, 2361, 2339, 1639, 1553, 1380, 1246 cm⁻¹. LRMS (ES+) calcd for $C_{13}H_{27}NO_5P$ (M+H⁺) 308, found 308.

III. Determination of Absolute Stereochemistry

The stereochemistry of two of the γ -addition products was assigned by correlation with known compounds. The stereochemistry of the other products was assigned by analogy.

(S)-3-methyl-2-(nitromethyl)butanal:³

 $Me_{N} \xrightarrow{O} i Pr Me - NO_{2} \xrightarrow{10\% (R)-1} Me_{N} \xrightarrow{O} NO_{2} \xrightarrow{O_{3}; SMe_{2}} O_{3}; SMe_{2} \xrightarrow{O} NO_{2}$

(R)-tert-butyl 2-(hydroxymethyl)pentylcarbamate:⁴



⁽³⁾ Enders, D.; Syrig, R.; Raabe, G.; Fernández, R.; Gasch, C.; Lassaletta, J.-M.; Llera, J.-M. Synthesis **1996**, 48–52.

⁽⁴⁾ Chi, Y.; Gellman, S. H. J. Am. Chem. Soc. 2006, 128, 6804–6805.

















.









Instrument 1 2/15/2009 11:34:25 AM SM

Page 1 of 3

Results obtained with enhanced integrator!

Instrument 1 2/15/2009 11:34:25 AM SM

Page 2 of 3

Totals : 6322.28271 83.78082

Peak RetTime Type Width 1 44.452 BB 1.0564 6322.28271 83.78082 100.0000 (min) (min) Area (mAU*s] Height [m/U] Area

â

g

Signal 5: DAD1 E, Sig=280,16 Ref=360,100

Results obtained with enhanced integrator!

Totals : 4.60207c4 599.87481

N

Re l

DAD1 E, Sig=280,16 Ref=360,100 (SM113007-1A D)

38.658

44-457

8

N ŝ R

DADT D. SIG-230, 18 Raf-360, 100 (SM113007-TA D)

38.694 1. 17,848

â

8888

20 4 5 5 8 5 MA

8 8 8 8 8 8 P

04D1 8, Sig=254,18 Ref=360,100 (SM113007-1A.D)

38.672

44-454

Peak RetTime Type Width
[min] [min]

N) I

30.672 BP 44.454 DB

0.6864 363.56030 6.28 1.0796 2.51485e4 329.08

6.28910 329.08517

1.4251 98.5749

[mAU*s]

Height [mAU]

Area

Area

2.55120e4

335.37427

Signal 1: DAD1 A,

Sig=254,4 Ref=360,100

h

Signal 2: DADI E, Sig=254,16 Ref=360,100

Results obtained with enhanced integrator!

Totals :

~

DADI C. Sig-210,8 Ref-360,100 (BM/13007-1A.D)

38.678

12

Totals :

N

38.678 BP 44.454 BB

0.6885 361.97119 1.1042 2.49286e4

6.2058

1.4313

2.52905e4

332.17361 325.96777

S-28

Peak RetTime Type

Width

(pin)

[c.W.s]

Height (nAV)

Area i

Area

[min]

4541

 $\frac{1}{1}$ -------11.46887 588.40594 1.5374 98.4626

(mín) (min) [:::AU*s] Area Height {mAU] Area

Signal 4: DADI D, Sig=230,16 Ref=360,100 Peak Retfime Type Width

Results obtained with enhanced integrator!

Totals :

1.08322e5 1299.39465

ы

80 98.4132

0.9852 1718.86450 1.3986 1.06603e5 0 29.07885 1270.31580

Peak RetTime Type (min) (min) [mAU*s] Height [mNU] Signal 3: DAD1 C, Sig=210,8 Ref=360,100

Width

Area

Area

Results obtained with enhanced integrator!

Data File C:\HPCHEM\1\DATA\SM\13007-1A.D

00-H

Sample Name

Operator

:: SM

Seq. Line : 9 Location : Vial 1 Inj : 1 Inj Volume : 5 µ1 L Inj Volume : 8 µ1

Table 2, entry 1

Sorted By : Signal Multiplier : 1.0000 Dilution : 1.0000 Use Multiplier & Dilution Factor with ISTDs

Š

Data File C:\HPCHEM\1\DATA\SM\13007-1A.D

Area Percent Report

Injection Date : 2/10/2009 10:29:36 PH

Acq. Instrument : Instrument 1 Different Inj Volume from Sequence ! Actual Acq. Hethod : C:\HFCHEN\1\HETHODS\05-60-1.H Last changed : J9/2007 8:41:24 Av by EL Analysis Method : C:\HFCHEN\1\METHODS\01-75-1.M Last changed : 2/10/2009 4:07:32 FM by SM Last changed : 2/10/2009 4:07:32 FM by SM

0 100 100 100 MAL



S-29



S--30

Page 2 of 2

Instrument 1 2/15/2009 11:39:59 AM SM Data File C:\HPCHEM\1\DATA\SH\13014-1.D Different Inj Volume from Sequence ! Actual Acq. Hethod : C.\HPCHEM\1\METHODS\05-30-1.M Last changed : 7/1/2008 11:11:04 AM by s1 Analysis Method : C.\HPCHEM\1\METHODS\01-75-1.M Last changed : 2/10/2009 4:07:12 PM by SH DADIA Ser250.4 Ref-250.100 (SMN13014-1 D) Acq. Operator Sample Name Injection Date æ 0 100 100 500 ΠAU - 50 15 200 PAL 30 N 8 8 8 8 8 ٠ Instrument DAD1 E. Sig=280, 16 Ref=360, 100 (SIA) 13014-1.0) DAD1 D, Sig=230,16 Ref=360,100 (SM13014-1 D) DAD1 C. Sig=210,8 Rof+360,100 (SM13014-1.D) DAD1 D. Sig=254,18 Rol-360,100 (SM113014-1.D) •• ş Instrument 1 2/12/2009 7:08:06 PM Seq. Line: 2 Location: Vial 1 Inj: 1 Inj Volume: 5 µl 1 Inj Volume: 6 µl 208 8:705 ĺN Z12 19:705 19,705 8 8 N) 24.073 24.075 24.071 24.078 24.084 N N Table 2, entry 4 Page 1 of 3 Me ž 1 Š Š Š Instrument 1 2/15/2009 11:39:59 AM SM Data File C:\HPCHEM\1\DATA\SM\13014-1.D Totals : Signal 5: DAD1 E, Sig=280,16 Ref=360,100 Peak RetTime Type # [min] Totals : Peak RetTime Type Width # [min] [min] Signal 4: DADI D, Sig=230,16 Ref=360,100 Results obtained with enhanced integrator! Totals : Peak RetTime Type Width Signal 3: DAD1 C, Totals : Peak Retlime Type Signal 2: DAD1 8, Sig=254,16 Ref=360,100 Sorted By : Signal Multiplier : 1.0000 Dilution : 1.0000 Use Multiplier & Dilution Factor with ISTDs ---- [------ [-----Results obtained with enhanced integrator! Totals : Peak RetTime Type Signal 1: DAD1 A, Sig=250,4 Ref=360,100 Results obtained with enhanced integrator! 1 Results obtained with enhanced integrator! ~ ~~ ю N N ÷ - { - - - - - - | - - - - | 19.706 BB 24.073 BB 19.712 BB 0 24.071 VB 0 19.705 BB 24.075 BB (min) 19.705 BB 24.084 BB 19.705 PB 24.078 BB (min) [#15] (nin) [ain] 0.5568 0.5178 Width [min] Sig=210,8 Ref=360,100 0.5661 1.27890e4 337.50305 0.6309 1368.70984 31.75201 0.5770 2.42892e4 633.8 0.6633 2641.82080 60.7 Width [min] 0.5545 5.43865e4 1331.56702 0.6111 6561.10986 145.23511 [min] (min) 0.5641 1.44734e4 0.5953 1543.08093 (min) Width 3291.18262 347.60388 Arca Percent Report 3638.78650 2.69310e4 6.09476e4 1476.80212 1.41577e4 (m/U*s) (mAU's) 1.60164e4 [#///#] [mAU's] [mAU* 3] Area Area Area Area 633.89062 60.75649 694.64712 369.25506 381.95975 35.91256 87.50635 8.14615 417.87231 Height [mAU] Keight (mAU) Height [mAU] Height [mAU] 95.65250 Height [mAU] 90.1904 9.8096 90.3656 9.6344 90.4473 9.5527 89.2348 10.7652 90.3324 9.6676 Area Area Area Area -----Area , 34

Page 2 of 3



S--32



S–33



S--34

Instrument 1 2/15/2009 11:37:29 AM SM		mALU 1447388 min 536, top (SMN13010-1.D) 1447388 min 536, top (SMN13010-1.D) 1447388 min 536, top (SMN13010-1.D) 1447388 min 536, top (SMN13010-1.D) 1447388 min 536, top (SMN13010-1.D)	0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 10 10 10 10 10 10 10 10 10 1	Different Inj Voluze from Sequence ' Act Acq. Hethod : C:\HECHEN1\WETHODS\05-99- Last changed : Z/11/2009 6:08:05 PH by SH Analysis Method : C:\HECHEN1\METHODS\0]-75- Last changed : Z/10/2009 4:07:32 PM by SH DADI A. Sur254.4Re-380,100 (SMN13016-1.b) MAU 400- 100- 100- 100- 100- 100- 100- 100-	Data File C:\HPCHEM\1\DATA\SH\13010-1.D Injection Date : 2/11/2009 6:34:57 PM Sample Mame : Acq. Operator : SM Acq. Instrument : Instrument 1
Page 1 of 3	50 60 70 60 min		5 50 60 mm		1	AD-H seq. Line : 2 location : Vial 1 Inj volume : 5 pl Inj volume : 5 pl
Totals : 3040.46798 145.51055 Instrument 1 2/15/2009 11:37:29 AM SM	Incars : 2.2310464 [1032.56614] Results obtained with enhanced integrator! Signal 5: DAD1 E, Sig*280,16 Ref=360,100 Peak RetTime Type Width Area # [min] [min] [mAU*s] [min] [min] [mAU*s] 1 14.738 HB 0.3204 2920.27173 140.53752 96.0468 2 18.099 PP 0.3360 120.19625 4.97300 3.9532	Totals : 4.43191e4 1782.82580 Results obtained with enhanced integrator! Signal 4: DADI D. Sig-230,16 Ref=360,100 Peak RetTime Type Width Area # [min] [min] 1.14.738 BB 0.3303 2.16140e4 1.14.738 BB 0.3714 896.49451 37.17045 3.9826	Actass : Results obtained with enhanced integrator: Signal 3: DADI C, Sig=210,8 Ref=360,100 Peak RetTime Type Width Area Height Area # [min] [min] [mAW*s] [mAU] 1 1 14.734 BB 0.3944 4.2231544 1696.68774 95.2896 2 18.097 BV 0.3708 2007.61768 86.13805 4.7104	Totals : 1.19937e4 568.91749 Results obtained with enhanced integrator! Signal 2: DAD1 B. Sig=254,16 Ref=360,100 Peak RetTime Type Width Area # [min] [min] 1.1730 BB 0.3244 0.3789 474.21533 1.14.736 BB 0.3789 1.14.736 BB 0.3789	Multiplier 1.0000 Dslution 1.0000 Use Multiplier 1.0000 Signal 1: DAD1 A, Sig=254,4 Ref=360,100 Peak RetTime Type Width Area Height # [min] Initi) [max] 1 14.739 BB 0.3246 1.15140e4 549.25677 95.9999 2 18.099 BB 0.3787 479.75781 19.66072 4.0001	Data File C:\NPCHEM\1\DATA\5M\13010-1.D Area Percent Report
Page 2 o			S–35			11





S--37

Instrument 1 2/15/2009 11:43:18 AM SM Data File C:\HPCHEM\1\DATA\SM\13018-1.D Acq. Instrument : Instrument 1 Different Inj Volume from Sequence : Actual Acq. Method : C:NBPCBENJUNETHODS\01-20-1.M Last changed : 6/6/2008 2:46:18 PH by SM Last changed : C:NECHENJUNETHODS\01-75-1.M Last changed : 2/10/2009 4:105:140S\01-75-1.M Last changed : 2/10/2009 4:005\01-75-1.M DAUTA.Sep-250.4 Ren-350,100 (SMN13016-ID) ved. njection Date ΠAU . P omple Hame 8 8 8 ą 1250 1000 250 15 ış me æ ē Ş 0 Operator DAD1 E. Sig=250,16 Rel=360,100 (SM113016-1.D) DAD1 D, Sig-230, 18 Ref=360, 100 (SMN13018-1.D) DAD1 C, Sig=210,8 Raf=360,100 (SMN)3018-1.D) DAD1 B. Sig-254, 18 Ref-360, 100 (SM113016-1.D) •• ş 2/12/2009 9:13:50 FH Seq. Line : 6 Location: Vial 3 Inj Volume : 5 ul Inj Volume : 6 µl a ð 12.5 12.5 12.5 12.5 () 13.561 () 73.561 () 73.69 () 73.69 () 73.69 () 73.69 () 73.69 () 73.69 () 73.69 () 73.561 () 13.593 13.593 *** *** *** *** *** *** *** 13.573 13.571 13.592 5 5 -BuO Table 3, entry 2 Page 1 of 3 17:451 17:452 3 17.450 17.5 7:45 17.5 18-18-17-19-8 B ΜØ ž Instrument 1 2/15/2009 11:43:18 AM SM Data File C:\HPCHEM\1\DATA\SM\13018-1.D Totals : Peak RetTime Type # [min] Signal 5: DAD1 E, Sig=280,16 Ref=360,100 Totals : Peak RetTime Type Signal 4: DADI D, Sig=230,16 Ref=360,100 Peak RetTime Type Signal 3: DAD1 C, Peak RetTime Type Width # [min] [min] Sorted By : Signal Multiplier : 1.0000 Dilution : 1.0000 Use Multiplier 6 Dilution Factor with ISTDs Totals : Signal 2: DADI B, Signal 1: DAD1 A, Sig=250,4 Ref=360,100 Results obtained with enhanced integrator! Ì Totals : Totals : Peak RetTime Type Results obtained with enhanced integrator! Results obtained with enhanced integrator! Results obtained with enhanced integrator! N 14 N) (m) N (min) 13.573 BP 17.452 PB 13.571 MM 17.450 BB 13.592 PB 17.450 BB (m1n) [m1n] ----------Widch [min] Sig=210,8 Ref=360,100 Sig=254,16 Ref=360,100 Width [min] 0.3365 Width 0.2515 0.3551 2858.91895 0.5061 5.43695e4 (min) Width [min] 6312.99707 214.3 28.01051 543.43402 Area Percent Report 24.54738 548.03314 5.72284e4 1820.55251 6626.62299 mAU*s [mAU*s] (mAU*s) 297.19044 [mAU*s] 571.44453 (mW"s) 572.58052 Area Area Area Area Area 1 6.42298e-1 9.55461 5 134.20009 1686.35242 14.37480 214.35719 228.73199 Reight (mAU) Height [mAU] Height [m/JU] 1.22115 18.36076 1.17634 10.92690 19.58991 Height [mAU] 10.19690 20.10324 Height [mNU] 4-7328 95-2672 4.6747 95.3253 4.9956 95.0044 4.2871 95.7129 Area 1 Area 1 Area Area Area

Page 2 of 3



S-39